Biostar Pharmaceuticals, Inc.
DelistedCIK 1418133fmd_0B24ZS234D3GBRQS5Q7N725SRRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2017, 30 periods
Latest annual · FY2016
Millions- Total revenues
- 2
- Gross profit
- 1
- Operating income
- (4)
- Net income
- (6)
- Free cash flow
- 5
Latest quarter · Q3 FY2017
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (1)
- Net income
- (0)
- Free cash flow
- (0)
Bulls and bears
Loading
News summary
An AI model writes the summary on request, from this company's recent filings only, and cites each filing it uses.
AI-written
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2013 to FY2016
- -64.4%
- Revenue, 5 yearsFY2011 to FY2016
- -51.8%
- Net income, 5 yearsFY2011 to FY2016
- n/m
Biostar Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2016 | FY2015 | Change | Source |
|---|---|---|---|---|
| Revenue | $2.4 million | $27.1 million | -91.2% | 10-K 2017-04-13 · proof |
| Gross profit | $915,174 | $11.1 million | -91.8% | 10-K 2017-04-13 · proof |
| Operating income | -$3.6 million | -$23.8 million | 10-K 2017-04-13 · proof | |
| Net income | -$5.7 million | -$25.1 million | 10-K 2017-04-13 · proof | |
| Cash from operating activities | $4.9 million | $5.9 million | -16.4% | 10-K 2017-04-13 · proof |
| Free cash flow | $4.9 million | $5.8 million | -15.6% | 10-K 2017-04-13 · proof |
| Total assets | $42.5 million | $51.4 million | -17.3% | 10-K 2017-04-13 · proof |
| Total liabilities | $5.6 million | $7.1 million | -20.8% | 10-K 2017-04-13 · proof |
| Cash and cash equivalents | $173,290 | $38,898 | +345.5% | 10-K 2017-04-13 · proof |
- What was Biostar Pharmaceuticals, Inc.'s revenue in fiscal 2016?
- Biostar Pharmaceuticals, Inc. reported revenue of $2.4 million for fiscal 2016 (the year ended Dec 31, 2016), against $27.1 million the year before (-91.2%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What was Biostar Pharmaceuticals, Inc.'s gross profit in fiscal 2016?
- Biostar Pharmaceuticals, Inc. reported gross profit of $915,174 for fiscal 2016 (the year ended Dec 31, 2016), against $11.1 million the year before (-91.8%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What was Biostar Pharmaceuticals, Inc.'s operating income in fiscal 2016?
- Biostar Pharmaceuticals, Inc. reported operating income of -$3.6 million for fiscal 2016 (the year ended Dec 31, 2016), against -$23.8 million the year before. Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What was Biostar Pharmaceuticals, Inc.'s net income in fiscal 2016?
- Biostar Pharmaceuticals, Inc. reported net income of -$5.7 million for fiscal 2016 (the year ended Dec 31, 2016), against -$25.1 million the year before. Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What was Biostar Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2016?
- Biostar Pharmaceuticals, Inc. reported cash from operating activities of $4.9 million for fiscal 2016 (the year ended Dec 31, 2016), against $5.9 million the year before (-16.4%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What was Biostar Pharmaceuticals, Inc.'s free cash flow in fiscal 2016?
- Biostar Pharmaceuticals, Inc. reported free cash flow of $4.9 million for fiscal 2016 (the year ended Dec 31, 2016), against $5.8 million the year before (-15.6%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What are Biostar Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2016, Biostar Pharmaceuticals, Inc. reported total assets of $42.5 million, against $51.4 million a year earlier (-17.3%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What are Biostar Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2016, Biostar Pharmaceuticals, Inc. reported total liabilities of $5.6 million, against $7.1 million a year earlier (-20.8%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
- What are Biostar Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2016, Biostar Pharmaceuticals, Inc. reported cash and cash equivalents of $173,290, against $38,898 a year earlier (+345.5%). Source: the 10-K filed with the SEC on Apr 13, 2017. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1418133&period_type=annual&limit=5"Information only, not investment advice.